Q2 momentum gone in Q3 Market to turn positive in '25, according to report We lower '25e EBITA by 13...
Redeye takes a positive view towards the acquisition of Data-AL.
Organic growth and earnings growth to remain high in Q4e Small estimate changes, adj.
Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Inve...
Finnair’s Q3 top line missed our estimate by almost 6% as average ticket fares continued to decrease...
DT’s Q3 earnings were slightly better than estimated as EBITA margin already topped 15%, however the...
Mangold uppdaterar sin syn på Miris. Bolaget har under det första halvåret sett en förbättrad markna...
Aspo’s Q3 earnings didn’t quite reach estimates as ESL’s EBITA remained low while Telko’s EUR 4.
Active Biotechs nya huvudfokus på myelofibros närmar sig start av två studier.
Redeye comments on Lifecare following today’s news that the company has completed a key development ...
Scientific advisory meetings with country-level EU authorities Market research shows payer interest ...
Redeye comments on W5’s Q3-results which were weaker than expected while order intake continued to i...
Shipping market was soft in Q3. ESL Shipping segment reported clean EBITA of EUR 3.
Higher occupancy and positive net letting Clearly outperforming Swedish office peers '25e P/CEPS ~14...
Redeye remains confident on the case despite some near-term uncertainty as the market climate contin...
Ahead of its Q3 2024 report, we take a slightly more cautious view towards NoHo Partners' revenue de...
The company's focus on profitability, cash flow and safeguarding its core service operations has sta...
Ahead of Taaleri's Q3 results due on 5 November, we lift our 2024 EBIT estimate by 22% to reflect th...
Redeye lowers its fair value range following a reconsideration of its financial estimates (following...
- Q3e: EEs 3.5m (4.2m), sales SEK 30m (40m), EBIT 38.
